Spegra - Dolutegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg 30 Tablets - Antiretroviral Medication

DOLUTEGRAVIR 50 mg + EMTRICITABINE 200 mg + TENOFOVIR ALAFENAMIDE 25 mg (Spegra) x 30 Tablets

Name: DOLUTEGRAVIR 50 mg + EMTRICITABINE 200 mg + TENOFOVIR ALAFENAMIDE 25 mg Tablet
Brand: Emcure Pharmaceuticals Ltd
SKU: spegra50
Price: 110.00 USD
Availability: InStock

~~$260.00~~ $110.00

Prescription Required

Spegra Tablet is a once-daily antiretroviral medication used to treat HIV-1 infection in adults. It combines three powerful ingredients Dolutegravir (50mg) + Emtricitabine (200mg) + Tenofovir Alafenamide (25mg) to effectively suppress the HIV virus, reduce its ability to multiply, and strengthen the immune system.

Generic Name	Dolutegravir (50mg) + Emtricitabine (200mg) + Tenofovir Alafenamide (25mg)
Manufacturer	Emcure Pharmaceuticals Ltd
Packing	30 Tablets in 1 Bottle
Prescribed For	HIV-1 Infection
Availability	In Stock
Shipping to	USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries.

Genuine Medicines

Quick Air Delivery

Secure Payment

24/7 Support

Benefits of DOLUTEGRAVIR 50 mg + EMTRICITABINE 200 mg + TENOFOVIR ALAFENAMIDE 25 mg

Helps manage and control HIV infection
Supports reduction of viral load in the body
May help strengthen immune system function
Combines multiple antiretroviral medicines in one treatment
Supports long-term HIV treatment management
Used under medical supervision

Side Effects

Headache
Nausea
Diarrhea
Insomnia (trouble sleeping)
Tiredness or fatigue
Abdominal discomfort
Weight gain

Dolutegravir, Emtricitabine and Tenofovir Alafenamide Medicine Information by Country

Dolutegravir, Emtricitabine and Tenofovir Alafenamide prices may vary between countries depending on the brand, strength, pack size, pharmacy, insurance coverage, government subsidies, taxes and local healthcare policies. The following resources provide country-specific pricing, reimbursement, regulatory or medicine information.

View Dolutegravir/emtricitabine/tenofovir alafenamide product information from MCAZ (Zimbabwe) – https://www.mcaz.co.zw/?download_id=7154&sdm_process_download=1
View Dolutegravir/emtricitabine/tenofovir alafenamide product information from TMDA (Tanzania) – https://www.tmda.go.tz/uploads/1678176936-T19H0685SmPCv1.pdf
View Dolutegravir-containing regimen clinical evidence on PubMed (International) – https://pubmed.ncbi.nlm.nih.gov/32504574/
View Tenofovir alafenamide patient medicine information from HIV.gov (USA) – https://clinicalinfo.hiv.gov/en/drugs/tenofovir-alafenamide/patient

Author

Reviewed By

Dr. Anju Gupta

Doctor of Medicine (MD) | Professional Interest in HIV/AIDS Care

Dr. Anju Gupta is a qualified medical practitioner with a professional interest in HIV care and long-term antiretroviral therapy. She focuses on helping patients understand how HIV medicines work, the importance of consistent treatment and the role of regular monitoring in maintaining viral suppression.

Disclaimer

This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.